Immuno – oncology

In the recent years, immunotherapy has become a potential strategy against various types of cancers. In light of this trend, two important components of the immune response signaling pathways – PD-1 (programmed cell death 1) and PD-L1 (programmed cell death ligand 1), are often mentioned. PD-1 is a cell membrane protein that has a role in limiting immune-induced tissue destruction at sites of active inflammation.